secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001558370-23-013590
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor reports Q2 net loss $7.4M; HOPE-3 DMD trial on track for Q4 2023 interim analysis
--------------------------------------------------------------------------------

- Cash, equivalents & marketable securities $37.8M as of June 30, down from $41.4M Dec 31, 2022.
- Q2 revenue $3.9M from Nippon Shinyaku upfront recognition vs. $0 in prior year; operating expenses $11.7M vs $7.3M.
- HOPE-3 Phase 3 DMD trial: 48 of ~68 patients randomized across 17 sites; enrollment completion and interim analysis expected Q4 2023.
- Held FDA Type-B clinical meeting to discuss CAP-1002 BLA pathway; final minutes awaited.
- Raised ~$2.1M net via ATM at avg $4.87/share; cash runway through Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023013590/0001558370-23-013590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023013590/capr-20230807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer